Pfizer reports positive Crohn’s disease data for Inflectra

Pfizer and Celltrion Healthcare have announced new clinical trial data further highlighting the strong performance of their biosimilar product Inflectra.

Results from the phase III study showed that for patients with moderate to severe Crohn's disease, treatment with Inflectra offered similar efficacy and safety to treatment with Remicade, the drug on which Inflectra is based.

The randomised 54-week trial enrolled 214 patients and met its primary endpoint by demonstrating the non-inferiority of Inflectra after six weeks, with a 71.4 percent response rate for Inflectra and a 75.2 percent rate for Remicade.

The study is also examining the treatment response and safety profile in patients when switching between the two therapies. Findings on this measure will be reported later this year.

Dr Sam Azoulay, senior vice-president and chief medical officer at Pfizer Essential Health, said: "In addition to existing data from the registration studies, real-world experience and the NOR-SWITCH trial, this data adds to the body of evidence supporting use of CT-P13 across its approved indications."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.